United States 778 +44.6%
Other Countries 231 +32.0%
TOTAL 1,470 +27.3%
In the United States, sales of Plavix(R) (consolidated by Bristol Myers Squibb -- BMS) reached $1,142 million in the first quarter, versus $789 million in the first quarter of 2007 when the product was still affected by the presence of a generic version.
In Europe, net sales of Plavix(R) were up 4.3% at EURO 461 million, though sales are still being affected by Germany.
In addition, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) recently issued a positive opinion recommending approval of the 300mg tablet of Plavix(R). This positive opinion from the CHMP must be ratified by the European Commission in the coming months before final approval.
In the Other Countries region, Plavix(R) reported a strong advance in
sales of 32.0% to EURO 231 million, supported by the product's success in
Japan (net sales of EURO 28 million, compared with EURO 4 million in the
first quarter of 2007).
Worldwide presence of Aprovel(R)/ Avapro(R)/ Karvea(R)
EURO million Q1 2008 Change on a comparable basis
Europe 245 +8.4%
United States 119 +8.2%
Other Countries 108 +22.7%
TOTAL 472 +11.3%
First-quarter worldwide sales of Aprovel(R)/Avapro(R)/Karvea(R) were up 11.3% at EURO 472 million.
Net sales by business segment -- Human Vaccines
First-quarter consolidated net sales for the Human Vaccines division rose by 2.8% to EURO 548 million.
Menactra(R) was the main growth driver, with net sales up 48.1% at EURO 99 million.
Net sales of Adacel(TM) (adult and
Copyright©2008 PR Newswire.
All rights reserved